| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.039 | 0.8 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | 0.046 | 0.8 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0092 | 0.8 |